---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-308316"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:34:52.804929+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Aeglea amends bylaws for universal proxy rules, DGCL changes, and meeting procedures

## Summary
- Board adopted amended bylaws effective December 15, 2022.
- Revised advance notice provisions: requires additional disclosures, limits nominees to directors up for election, and mandates nominee interviews.
- Added compliance measures for SEC Rule 14a-19 universal proxy, including certification and notice requirements.
- Updated adjournment procedures and stockholder meeting conduct; added emergency bylaw for quorum failure.
- Conformed notice provisions to DGCL electronic transmission amendments.

## SEC filing metadata
- accession: 0001193125-22-308316
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312522308316/0001193125-22-308316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312522308316/d414065d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-308316
- JSON: https://secwatch.observer/filing/0001193125-22-308316.json
- Plain text: https://secwatch.observer/filing/0001193125-22-308316.txt

## Key facts
- Governance Changes
  Spyre Therapeutics, Inc.: Amended and restated bylaws to conform to DGCL amendments and universal proxy rules, including revisions to stockholder meeting procedures, advance notice provisions, and emergency bylaws (effective 2022-12-15).
  - Change: bylaw amendment
  - Effective: 2022-12-15
  source text: On December 15, 2022, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Aeglea Biotherapeutics, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312522308316/0001193125-22-308316-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.